Great Point Partners LLC Boosts Stock Position in Evolus, Inc. (NASDAQ:EOLS)

Great Point Partners LLC grew its stake in shares of Evolus, Inc. (NASDAQ:EOLS) by 1,052.1% during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 2,192,816 shares of the company’s stock after buying an additional 2,002,487 shares during the period. Evolus accounts for 3.6% of Great Point Partners LLC’s portfolio, making the stock its 11th biggest holding. Great Point Partners LLC owned 3.85% of Evolus worth $18,551,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also recently made changes to their positions in the company. Cubist Systematic Strategies LLC lifted its holdings in Evolus by 620.8% in the 1st quarter. Cubist Systematic Strategies LLC now owns 107,034 shares of the company’s stock worth $906,000 after purchasing an additional 92,184 shares in the last quarter. Two Sigma Investments LP lifted its holdings in Evolus by 74.2% in the 1st quarter. Two Sigma Investments LP now owns 32,500 shares of the company’s stock worth $275,000 after purchasing an additional 13,844 shares in the last quarter. Deutsche Bank AG lifted its holdings in Evolus by 38.4% in the 1st quarter. Deutsche Bank AG now owns 23,169 shares of the company’s stock worth $196,000 after purchasing an additional 6,427 shares in the last quarter. Boothbay Fund Management LLC lifted its holdings in Evolus by 2.3% in the 1st quarter. Boothbay Fund Management LLC now owns 1,106,449 shares of the company’s stock worth $9,361,000 after purchasing an additional 25,139 shares in the last quarter. Finally, Renaissance Technologies LLC lifted its holdings in Evolus by 148.0% in the 1st quarter. Renaissance Technologies LLC now owns 226,429 shares of the company’s stock worth $1,916,000 after purchasing an additional 135,129 shares in the last quarter. 65.15% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Evolus

In other Evolus news, CFO Sandra Beaver sold 3,178 shares of the company’s stock in a transaction on Wednesday, September 6th. The stock was sold at an average price of $9.70, for a total value of $30,826.60. Following the transaction, the chief financial officer now owns 113,368 shares of the company’s stock, valued at approximately $1,099,669.60. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other Evolus news, CFO Sandra Beaver sold 3,178 shares of the company’s stock in a transaction on Wednesday, September 6th. The stock was sold at an average price of $9.70, for a total value of $30,826.60. Following the transaction, the chief financial officer now owns 113,368 shares of the company’s stock, valued at approximately $1,099,669.60. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Vikram Malik acquired 174,967 shares of the business’s stock in a transaction on Tuesday, August 15th. The stock was acquired at an average cost of $7.41 per share, for a total transaction of $1,296,505.47. Following the transaction, the director now directly owns 275,550 shares in the company, valued at $2,041,825.50. The disclosure for this purchase can be found here. 5.40% of the stock is currently owned by corporate insiders.

Evolus Trading Down 0.1 %

Shares of NASDAQ EOLS traded down $0.01 during trading hours on Tuesday, hitting $9.54. 9,362 shares of the company traded hands, compared to its average volume of 565,137. The stock has a market capitalization of $543.49 million, a price-to-earnings ratio of -8.16 and a beta of 1.60. The company has a current ratio of 2.33, a quick ratio of 1.85 and a debt-to-equity ratio of 10.37. The company’s 50 day moving average price is $8.92 and its 200 day moving average price is $8.71. Evolus, Inc. has a 12 month low of $6.51 and a 12 month high of $11.49.

Evolus (NASDAQ:EOLS) last released its earnings results on Wednesday, August 2nd. The company reported ($0.28) earnings per share for the quarter, missing the consensus estimate of ($0.26) by ($0.02). The company had revenue of $49.35 million for the quarter, compared to the consensus estimate of $46.12 million. Evolus had a negative net margin of 39.36% and a negative return on equity of 507.42%. On average, equities research analysts anticipate that Evolus, Inc. will post -0.76 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts recently commented on the company. Needham & Company LLC reissued a “buy” rating and issued a $22.00 price target on shares of Evolus in a report on Thursday, August 3rd. Truist Financial upped their price objective on Evolus from $14.00 to $18.00 in a report on Friday, May 26th. Mizuho upped their price objective on Evolus from $17.00 to $20.00 in a report on Wednesday, June 7th. Finally, HC Wainwright upped their price objective on Evolus from $16.00 to $27.00 and gave the stock a “buy” rating in a report on Thursday, August 3rd.

Evolus Profile

Evolus, Inc, a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.